SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
Certification and Notice of Termination of Registration
under Section 12(g) of the Securities Exchange Act of 1934
or Suspension of Duty to File Reports under Section 13
and 15(d) of the Securities Exchange Act of 1934
Commission File Number 0-8049
Circa Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
33 Ralph Avenue
Copiague, New York 11726 (516) 842-8383
(Address, including zip code and telephone number, including
area code, of registrant's principal executive offices)
Common Stock, par value $0.01 per share
(Title of each class of securities covered by this Form)
None
(Title of all other classes of securities for which a duty
to file reports under Section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1)(i) X Rule 12h-3(b)(1)(ii)
Rule 12g-4(a)(1)(ii) Rule 12h-3(b)(2)(i)
Rule 12g-4(a)(2)(i) Rule 12h-3(b)(2)(ii)
Rule 12g-4(a)(2)(ii) Rule 15d-6
Rule 12h-3(b)(1)(i)
Approximate number of holders of record as of the certification or notice date:
1,819
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, Circa Pharmaceuticals, Inc. has caused this certification/notice to be
signed on its behalf by the undersigned duly authorized person.
CIRCA PHARMACEUTICALS, INC.
BY: /s/ MELVIN SHAROKY, M.D.
DATE: July 18, 1995 Melvin Sharoky, M.D.
President and Chief Executive Officer
